Advertisement
Advertisement
U.S. markets open in 7 hours 14 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ESSA Pharma Inc. (EPIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8200-0.3300 (-10.48%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close3.1500
Open3.1100
Bid0.0000 x 1200
Ask0.0000 x 1100
Day's Range2.8200 - 3.1100
52 Week Range2.8200 - 29.7000
Volume158,113
Avg. Volume188,790
Market Cap124.248M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-0.8660
Earnings DateAug 15, 2022 - Aug 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EPIX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ESSA Pharma Inc.
    Daily – Vickers Top Insider Picks for 06/08/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    27 days agoArgus Research
View more
  • CNW Group

    ESSA Pharma Insiders Establish Automatic Securities Disposition Plans

    ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that each of its President and Chief Executive Officer, David R Parkinson and its Executive Vice President and Chief Operating Officer, Peter Virsik (collectively, the "Participants"), have established Automatic Securities Disposition Plans ("ASDPs") in accordance with applicable United States and Canadian s

  • Benzinga

    ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer

    ESSA Pharma Inc (NASDAQ: EPIX) presented clinical results from the Phase 1a dose-escalation study of EPI-7386 as a monotherapy for metastatic castration-resistant prostate cancer (mCRPC) resistant to current standard-of-care therapies. The initial data from 36 patients demonstrate that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients. In five patients with measurable disease who were

  • CNW Group

    ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented clinical results from the Phase 1a dose escalation study of EPI-7386, ESSA's first-in-class N-terminal domain ("NTD") androgen receptor ("AR") inhibitor, as a monotherapy for the treatment of patients with metastatic castration-resistant prostate cancer ("mCRPC") resistant to current standard-of-care therap

Advertisement
Advertisement